Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Jury still out on gemcitabine/nab-paclitaxel as treatment for pancreatic cancer

Publish date:: June 5, 2019

Key clinical point: While gemcitabine plus nab-paclitaxel did not demonstrate prolonged independently assessed disease-free survival versus gemcitabine as adjuvant pancreatic cancer treatment, longer follow-up is needed to evaluate overall survival.

Major finding: Median independently assessed disease-free survival was 19.4 months for nab-paclitaxel/gemcitabine and 18.8 months for gemcitabine (HR, 0.88; P = .1824).

Study details: Results of the randomized phase 3 APACT trial of 866 surgically resected pancreatic cancer patients enrolled at 179 sites in 21 countries.

Disclosures: Dr. Tempero reported disclosures related to Abbie, Advance Medical, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, BioPharm Communications, Celgene, CPRIT, EcoR1 Capital, Eisai, FibroGen, Halozyme, Ignyta, Immunovia, Merck, Pharmacyclics, Pharmacyte Biotech, and Tocagen.

Citation:

Tempero MA et al. ASCO 2019, Abstract 4000.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,